Urology Medical News about Docetaxel, oxaliplatin, urothelial carcinoma

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

A phase II study of docetaxel and oxaliplatin for second-line treatment of urothelial carcinoma
Chemotherapy, 07/31/09

Srinivas S et al. - In a trial to evaluate the efficacy and safety of docetaxel and oxaliplatin in metastatic urothelial cancer pts who had received prior platinum therapy, it was concluded that second-line docetaxel and oxaliplatin in metastatic urothelial cancer is safe and tolerable but did not achieve an appreciable response rate.

Methods

Pts with metastatic urothelial cancer, who had disease progression after platinum therapy, were treated with docetaxel 75 mg/m2 and oxaliplatin 85 mg/m2 every 3 wks until disease progression or intolerable toxicity.

Results

11 pts were enrolled.
Pts had low or intermediate Bajorin risk.
Median number of cycles administered was 2.
1 pt achieved near complete response.
3 pts experienced disease stabilization, resulting in a disease-control rate of 36%.
Median overall survival was 7 mos.
Most common toxicities were fatigue and anemia (50%).

<< Previous
Sunitinib malate for metastatic castration-resistant prostate...

Next >>
Plasma Selenium, Manganese Superoxide Dismutase, and...